Fate Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 03, 2022 at 04:08 pm EDT
Share
Fate Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 76.11 million compared to USD 55.13 million a year ago. Basic loss per share from continuing operations was USD 0.79 compared to USD 0.58 a year ago.
For the six months, net loss was USD 141.8 million compared to USD 100.22 million a year ago. Basic loss per share from continuing operations was USD 1.47 compared to USD 1.07 a year ago.
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Companyâs platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.
FATE THERAPEUTICS, INC. 
